Related Experiment Videos
Clinical experience with aztreonam in Germany and Austria
Reviews of Infectious Diseases
|November 1, 1985
Summary
Aztreonam demonstrated high clinical efficacy in treating bacterial infections, particularly in the urinary and respiratory tracts. This antibiotic showed good microbiologic cure rates and favorable tissue penetration, with no observed nephrotoxicity.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Aztreonam is a monobactam antibiotic used for Gram-negative bacterial infections.
- Urinary tract and lower respiratory tract infections are common indications for antibiotic therapy.
Purpose of the Study:
- To evaluate the clinical and microbiologic efficacy of aztreonam.
- To assess aztreonam's safety profile, including nephrotoxicity.
- To determine aztreonam's pharmacokinetic properties and tissue distribution.
Main Methods:
- Clinical trial involving 146 hospitalized patients treated with aztreonam.
- Comparison with control drugs (gentamicin, cefotaxime, cefamandole, tobramycin).
- Pharmacokinetic studies in geriatric patients and healthy volunteers.
Main Results:
- 142 of 146 patients (97%) achieved satisfactory clinical response with aztreonam.
- Initial microbiologic cure in 84% of patients; relapse/reinfection in 28 patients.
- Aztreonam showed successful perioperative treatment in 10 of 11 patients.
- No nephrotoxicity observed; satisfactory tissue concentrations achieved.
Conclusions:
- Aztreonam is highly effective and safe for treating Gram-negative bacterial infections.
- Dosage adjustment in geriatric patients should consider creatinine clearance.
- Aztreonam achieves therapeutic concentrations in various body tissues.